retatrutide phase 2 trial results weight loss obesity triple agonist This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial https://t.co/jNL1GNnHPT #Endocrinology Triple hormone receptor agonist retatrutide

For six weeks, they either took a GLP-1 medication (exenatide, brand name Bydureon ) or a placebo

Should I stop retatrutide if I have diarrhea

This new drug combines semaglutide with amylin and calcitonin receptor agonists

Activities that were abandoned years ago, playing basketball, hiking, wrestling with the kids, become possible again

Members under 21 may still qualify via EPSDT, and non-weight-loss indications (like Zepbound for sleep apnea) may still get prior authorization

At Adonis Saremi, MD , our Microdosing GLP-1 Program in Irvine, CA offers a physician-designed alternative: precisely calibrated sub-standard doses that preserve the metabolic and appetite-regulation benefits of GLP-1 medications while minimizing the side-effect burden that causes many patients to discontinue